
Profitability, historical returns, and peer comparisons.
According to Brainstorm Cell Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is 103.69%. This represents a change of 300.39% compared to the average of 25.90% of the last 4 quarters.
The mean historical ROE of Brainstorm Cell Therapeutics Inc. over the last ten years is 67.10%. The current 103.69% ROE has changed 54.52% with respect to the historical average. Over the past ten years (40 quarters), BCLI's ROE was at its highest in in the December 2022 quarter at 166.43%. The ROE was at its lowest in in the March 2019 quarter at -1542.02%.
Average
67.10%
Median
-67.27%
Minimum
-278.07%
Maximum
805.21%
Discovering the peaks and valleys of Brainstorm Cell Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 230.18%
Maximum Annual ROE = 805.21%
Minimum Annual Increase = -736.80%
Minimum Annual ROE = -278.07%
| Year | ROE | Change |
|---|---|---|
| 2025 | 100.15% | -166.90% |
| 2024 | -149.70% | -142.30% |
| 2023 | 353.89% | -56.05% |
| 2022 | 805.21% | -736.80% |
| 2021 | -126.45% | 40.97% |
| 2020 | -89.70% | -147.15% |
| 2019 | 190.24% | -168.41% |
| 2018 | -278.07% | 230.18% |
| 2017 | -84.22% | 67.39% |
| 2016 | -50.31% | -16.26% |
The current ROE of Brainstorm Cell Therapeutics Inc. (BCLI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
101.44%
5-year avg
196.62%
10-year avg
67.10%
Brainstorm Cell Therapeutics Inc.’s ROE is less than NKGen Biotech, Inc. Common Stock (150.91%), less than International Stem Cell Corporation (19.43%), greater than ReNeuron Group plc (-72.37%), greater than Lineage Cell Therapeutics, Inc. (-71.14%), greater than BioRestorative Therapies, Inc. (-423.84%),
| Company | ROE | Market cap |
|---|---|---|
| 150.91% | $1.44M | |
| 19.43% | $1.16M | |
| -72.37% | $62.89K | |
| -71.14% | $249.16M | |
| -423.84% | $2.04M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Brainstorm Cell Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Brainstorm Cell Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Brainstorm Cell Therapeutics Inc.'s ROE?
How is the ROE calculated for Brainstorm Cell Therapeutics Inc. (BCLI)?
What is the highest ROE for Brainstorm Cell Therapeutics Inc. (BCLI)?
What is the 3-year average ROE for Brainstorm Cell Therapeutics Inc. (BCLI)?
What is the 5-year average ROE for Brainstorm Cell Therapeutics Inc. (BCLI)?
How does the current ROE for Brainstorm Cell Therapeutics Inc. (BCLI) compare to its historical average?